Overview of Actionable Mutations and Molecular Profiling in NSCLC
Expert oncologist Roy Herbst, MD, PhD, provides a comprehensive overview of actionable mutations and molecular profiling in NSCLC.
Improving Targeted Therapeutics in NSCLC Management
Before closing out his discussion on NSCLC, Sandip Patel, MD, shares his excitement for evolving targeted strategies and improved patient outcomes.
Paul G. Richardson, MD, Highlights Benefits of Continuous Lenalidomide Maintenance Vs ASCT in Newly Diagnosed Myeloma
At 2022 ASCO, Paul G. Richardson, MD, dives into results of the DETERMINATION study, which examined triplet therapy with lenalidomide plus either lenalidomide maintenance until progression or autologous stem transplantation in newly diagnosed multiple myeloma.
Bispecific Antibodies in the Treatment of RRMM
Comprehensive perspectives on the role of bispecific antibodies in the treatment of relapsed/refractory multiple myeloma.
CAR-T Therapies Therapy in RRMM
A brief review of the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
Biagio Ricciuti, MD, Discusses Correlative Analysis of PD-L1 Expression in NSCLC Treated With Pembrolizumab Monotherapy
Biagio Ricciuti, MD, spoke about results of pembrolizumab monotherapy administration in patients with non–small cell lung cancer who had a PD-L1 tumor proportion score of 90% or more.
Saad Z. Usmani, MD, MBA, FACP, Discusses Results of SWOG 1211 Examining RVd Plus Elotuzumab in Newly Diagnosed Myeloma
Saad Z. Usmani, MD, MBA, FACP, discusses the use of lenalidomide, bortezomib, and dexamethasone with or without elotuzumab for newly diagnosed, high-risk multiple myeloma.
Ola Landgren, MD, PhD, on the Future of Multiple Myeloma Research
Ola Landgren, MD, PhD, highlights how future research efforts in multiple myeloma are likely to focus on chemotherapy-free regimens and minimal residual disease detection.
Catherine S. Diefenbach, MD, Talks Future of CAR T-cell Therapy Following Liso-Cel Approval in Second-Line LBCL
Catherine S. Diefenbach, MD, spoke about refining understanding of CAR T-cell therapies after the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma.
Scope and Methods of the PARADIGM Study and Expert Commentary on Treatment Decision-Making
Shilpa Gupta, MD, describes the scope and methods of the PARADIGM study, which examines recent systemic anti-cancer treatment patterns in la/mUC.
Overview of Locally Advanced/Metastatic Urothelial Carcinoma
Vinit Makkar, MD, provides a brief overview of locally advanced/metastatic urothelial carcinoma (la/mUC), available first-line (1L) and first-line maintenance (1LM) treatment options, and unmet needs in the field.
Therapy Strategies for Primary Myelofibrosis
Raajit Rampal, MD, PhD, shares the treatment options he would consider for the presented clinical scenario.
CRESTONE Trial of Seribantumab in Solid Tumors With NRG1 Fusions: Efficacy Data
Shared insight on key efficacy data from the CRESTONE clinical trial of seribantumab therapy in solid tumors with NRG1 fusions.
CRESTONE Trial of Seribantumab in Solid Tumors With NRG1 Fusions: Trial Design and Safety Data
Expert perspectives on the trial design of and safety data from CRESTONE, which analyzed seribantumab therapy in solid tumors with NRG1 fusions.
Approved Treatments for Myelofibrosis
A review of the approved treatments for myelofibrosis, including dosing guidelines and supporting clinical trial data.
Clinical Scenario: Patient with Primary Myelofibrosis
Dr John Mascarenhas presents a patient case scenario of a 68-year-old woman with a common presentation of primary myelofibrosis.
The JAK/STAT Pathway and Myelofibrosis
Raajit Rampal, MD, describes the JAK-STAT pathway and how it’s fundamental to all types of myelofibrosis.
Patient Profile 3: A 57-Year-Old Woman With Triple-Class Refractory MM
Moving to the last patient profile, expert panelists discuss a patient with triple-class refractory multiple myeloma managed with BCMA-targeting bispecific therapy.
EGFR-Targeted Therapy in NSCLC: Optimizing Sequencing and Combinations
Focusing on the broader treatment armamentarium for EGFR-mutated NSCLC, Sandip Patel, MD, considers possible sequencing and combination strategies.
Optimizing Outcomes in Patients with HER2+ BC with Current and Novel Therapies
A panel of experts discusses factors to consider when selecting treatment for patients with HER2+ mBC including brain metastases, quality of life, and treatment resistance.
